Table 5.

Median duration of registry follow‐up until stop/switch for first‐line, second‐line and third‐line treatments; patients with psoriasis initiating new therapy during the registry

	Ustekinumab	Infliximab	Adalimumab	Etanercept	All
First‐line therapy starts, N	361	63	402	289	1115
Median, Years	1.98	2.73	2.70	3.08	2.50
Second‐line therapy starts, N	566	93	622	155	1436
Median, Years	2.88	3.04	3.77	3.15	3.24
Third‐line therapy starts, N	551	103	197	71	922
Median, Years	3.49	3.34	3.92	3.22	3.52